Verastem sinks after 27% response rate in ovarian cancer study

Verastem is stinking after the company provided an update on its RAMP 201 trial, saying 115 patients with recurrent low-grade serious ovarian cancer were treated with the combination of avutometinib and defactinib, of which 109 patients had measurable tumor masses at baseline and were eligible for formal efficacy evaluation as of the data cutoff. As of the data cutoff, all patients had a minimum follow-up of five months since enrollment. Confirmed objective response rates by blinded independent central review for patients evaluable for efficacy were 27% in all patients. Of the 32 patients who remained on study treatment at the data cutoff, 14 achieved a best response rate of stable disease or unconfirmed partial response and therefore have the potential to achieve a formal objective response upon further treatment. 60% of evaluable patients achieved either a complete response, partial response, or stable disease response for six months or longer. Shares of Verastem are down 59%, or $7.20, to $4.99 in premarket trading.